Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study
暂无分享,去创建一个
M. Exline | Akram Khan | W. Self | A. Ginde | C. Lindsell | D. Hager | N. Shapiro | M. McMorrow | A. Duggal | K. Gibbs | A. Lauring | E. Martin | J. Chappell | N. Thornburg | Carlos G. Grijalva | M. Gaglani | N. Halasa | H. Talbot | J. Casey | J. Steingrub | Steven Y. Chang | M. Tenforde | J. Rhoads | Jennie H. Kwon | I. Peltan | Jennifer G. Wilson | A. Mohamed | Samuel M Brown | D. Surie | C. Mallow | L. Busse | S. Lester | D. Files | A. Zepeski | A. E. Frosch | N. J. Johnson | M. Patel | T. McNeal | J. P. Rhoads | K. Adams | SoHee Park | A. Frosch | Jennifer G. Wilson | N. Johnson | J. Kwon | Samuel M. Brown | Christopher Mallow | Sohee Park
[1] P. Austin,et al. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes , 2022, JAMA network open.
[2] H. D. de Melker,et al. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections , 2022, Nature Communications.
[3] William F. Fadel,et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[4] D. Barouch,et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5 , 2022, The New England journal of medicine.
[5] A. Fomsgaard,et al. Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine , 2022, JAMA network open.
[6] M. Nussenzweig,et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost , 2022, Nature.
[7] P. Offit. Covid-19 Boosters — Where from Here? , 2022, The New England journal of medicine.
[8] J. L. Bernal,et al. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study , 2022, Nature Communications.
[9] William F. Fadel,et al. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[10] J. Ioannidis. Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies , 2022, BMJ Evidence-Based Medicine.
[11] J. L. Bernal,et al. COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England , 2022, The Lancet Infectious Diseases.
[12] M. Exline,et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study , 2022, BMJ.
[13] S. Gharbia,et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.
[14] Jeffrey G. Klann,et al. Distinguishing Admissions Specifically for COVID-19 from Incidental SARS-CoV-2 Admissions: A National EHR Research Consortium Study , 2022, medRxiv.
[15] Samuel S. Shepard,et al. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[16] William F. Fadel,et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[17] P. Noble,et al. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One Hospital, California, July 15–September 23, 2021, and December 21, 2021–January 27, 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[18] William F. Fadel,et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[19] K. Bruxvoort,et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants , 2022, Nature Medicine.
[20] A. Walls,et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement , 2021, bioRxiv.
[21] G. Hripcsak,et al. COVID-19 vaccination effectiveness rates by week and sources of bias , 2021, medRxiv.
[22] M. Kraemer,et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.
[23] K. Mølbak,et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study , 2021, medRxiv.
[24] Anthony Z. Matolek,et al. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[25] A. Sigal,et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection , 2021, medRxiv.
[26] S. Hoehl,et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies , 2021, medRxiv.
[27] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.
[28] M. Exline,et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. , 2021, JAMA.
[29] David W. McDonald,et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[30] L. Abu-Raddad,et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.
[31] Manish M Patel,et al. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States , 2021, Clinical Infectious Diseases.
[32] Samuel M. Brown,et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] A. Marchant,et al. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans , 2021, Nature Reviews Immunology.
[34] G. Kang,et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization , 2021, Vaccine.
[35] M. Davenport,et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection , 2021, Nature Reviews Immunology.
[36] Manish M Patel,et al. Postlicensure Evaluation of COVID-19 Vaccines. , 2020, JAMA.
[37] J. Quick. nCoV-2019 sequencing protocol v3 (LoCost) , 2020 .
[38] Edward C. Holmes,et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology , 2020, Nature Microbiology.
[39] J. Sterne,et al. Collider bias undermines our understanding of COVID-19 disease risk and severity , 2020, Nature Communications.
[40] Eric J Tchetgen Tchetgen,et al. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. , 2016, American journal of epidemiology.
[41] S. Greenland,et al. Simulation study of confounder-selection strategies. , 1993, American journal of epidemiology.
[42] M. Lipsitch,et al. The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology. , 2019, Epidemiology.